[go: up one dir, main page]

MX2018004532A - Combinacion de trazodona y gabapentina para el tratamiento de dolor. - Google Patents

Combinacion de trazodona y gabapentina para el tratamiento de dolor.

Info

Publication number
MX2018004532A
MX2018004532A MX2018004532A MX2018004532A MX2018004532A MX 2018004532 A MX2018004532 A MX 2018004532A MX 2018004532 A MX2018004532 A MX 2018004532A MX 2018004532 A MX2018004532 A MX 2018004532A MX 2018004532 A MX2018004532 A MX 2018004532A
Authority
MX
Mexico
Prior art keywords
combination
trazodone
pain
treatment
gabapentina
Prior art date
Application number
MX2018004532A
Other languages
English (en)
Other versions
MX380433B (es
Inventor
Garrone Beatrice
Durando Lucia
Calisti Fabrizio
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2018004532A publication Critical patent/MX2018004532A/es
Publication of MX380433B publication Critical patent/MX380433B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende una combinación de trazodona o una sal de la misma, y gabapentina o una sal o profármaco de la misma, teniendo la combinación un efecto sinérgico en el tratamiento de dolor.
MX2018004532A 2015-10-22 2016-10-17 Combinación de trazodona y gabapentina para el tratamiento de dolor. MX380433B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191024 2015-10-22
PCT/EP2016/074835 WO2017067870A1 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain

Publications (2)

Publication Number Publication Date
MX2018004532A true MX2018004532A (es) 2018-09-12
MX380433B MX380433B (es) 2025-03-12

Family

ID=54345445

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004532A MX380433B (es) 2015-10-22 2016-10-17 Combinación de trazodona y gabapentina para el tratamiento de dolor.

Country Status (28)

Country Link
US (2) US10786498B2 (es)
EP (2) EP3364975B1 (es)
JP (1) JP6924184B2 (es)
KR (1) KR102691296B1 (es)
CN (1) CN108174599B (es)
AR (1) AR106415A1 (es)
AU (1) AU2016341063B2 (es)
BR (1) BR112018007374B1 (es)
CA (1) CA2999389C (es)
CY (1) CY1124229T1 (es)
DK (2) DK3364975T3 (es)
EA (2) EA037838B1 (es)
ES (2) ES2879392T3 (es)
FI (1) FI3881845T3 (es)
GE (2) GEP20207145B (es)
HR (2) HRP20210832T1 (es)
HU (2) HUE054653T2 (es)
IL (1) IL258316B (es)
LT (2) LT3881845T (es)
MD (2) MD3364975T2 (es)
MX (1) MX380433B (es)
PL (2) PL3364975T3 (es)
PT (2) PT3364975T (es)
RS (2) RS66607B1 (es)
SI (2) SI3881845T1 (es)
SM (2) SMT202100352T1 (es)
UA (1) UA122245C2 (es)
WO (1) WO2017067870A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900006602A1 (it) * 2019-05-07 2020-11-07 Acraf Composizione farmaceutica per il trattamento del dolore neuropatico
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025675A1 (en) 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
WO2006069293A2 (en) 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US9695380B2 (en) * 2007-07-18 2017-07-04 Dow Global Technologies Llc Water-glycol hydraulic fluid compositions
EP2184986A4 (en) 2007-08-06 2010-12-15 Trinity Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
EP2315742A2 (en) * 2008-07-02 2011-05-04 Teva Pharmaceutical Industries Ltd. Gabapentin enacarbil salts and processes for their preparation
EP2727473A4 (en) 2011-06-28 2015-05-06 Vivozon Inc COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF

Also Published As

Publication number Publication date
RS66607B1 (sr) 2025-04-30
FI3881845T3 (fi) 2025-04-08
SMT202100352T1 (it) 2021-07-12
LT3881845T (lt) 2025-04-25
HK1252359A1 (zh) 2019-05-24
IL258316B (en) 2022-08-01
BR112018007374B1 (pt) 2023-11-28
US10786498B2 (en) 2020-09-29
EP3881845A2 (en) 2021-09-22
GEAP202014778A (en) 2020-03-10
IL258316A (en) 2018-06-28
EA202190626A3 (ru) 2021-09-30
US20200316060A1 (en) 2020-10-08
SI3364975T1 (sl) 2021-08-31
UA122245C2 (uk) 2020-10-12
PL3364975T3 (pl) 2021-11-02
EP3364975A1 (en) 2018-08-29
CN108174599A (zh) 2018-06-15
JP2018531259A (ja) 2018-10-25
RS61989B1 (sr) 2021-07-30
PL3881845T3 (pl) 2025-05-12
CN108174599B (zh) 2021-09-03
PT3881845T (pt) 2025-02-13
SMT202500150T1 (it) 2025-05-12
ES3015662T3 (en) 2025-05-07
ES2879392T3 (es) 2021-11-22
HRP20250248T1 (hr) 2025-04-11
EA037838B1 (ru) 2021-05-26
MD3881845T2 (ro) 2025-06-30
KR102691296B1 (ko) 2024-08-05
CA2999389C (en) 2023-12-19
AU2016341063B2 (en) 2022-04-14
SI3881845T1 (sl) 2025-05-30
EP3881845A3 (en) 2021-09-29
US20180296553A1 (en) 2018-10-18
EA202190626A2 (ru) 2021-06-30
EP3881845B1 (en) 2025-01-15
US11752147B2 (en) 2023-09-12
HRP20210832T1 (hr) 2021-08-06
PT3364975T (pt) 2021-05-27
CY1124229T1 (el) 2022-05-27
DK3881845T3 (da) 2025-03-24
HUE054653T2 (hu) 2021-09-28
DK3364975T3 (da) 2021-06-21
AU2016341063A1 (en) 2018-04-26
EP3364975B1 (en) 2021-04-07
KR20180063314A (ko) 2018-06-11
CA2999389A1 (en) 2017-04-27
HUE071186T2 (hu) 2025-08-28
EA201890911A1 (ru) 2018-09-28
WO2017067870A1 (en) 2017-04-27
BR112018007374A2 (pt) 2018-10-23
MX380433B (es) 2025-03-12
LT3364975T (lt) 2021-09-10
JP6924184B2 (ja) 2021-08-25
AR106415A1 (es) 2018-01-10
MD3364975T2 (ro) 2021-09-30
GEP20207145B (en) 2020-08-25

Similar Documents

Publication Publication Date Title
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112017007863A2 (pt) composição para o tratamento de condições envolvendo dor muscular
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
CY1124229T1 (el) Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2019003697A (es) Sal de metformina de elafibranor que muestra una actividad doble para el tratamiento de la obesidad asociada a la esteatohepatitis no alcoholica (nash) y a la hipertrigliceridemia.